Liso-Cel in R/R CLL/SLL: Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study
By
SOHO 2023 Eleventh Annual Meeting
FEATURING
Tanya Siddiqi
By
SOHO 2023 Eleventh Annual Meeting
FEATURING
Tanya Siddiqi
Disclaimer: On March 14, 2024 the FDA approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Comments 0
Login to view comments.
Click here to Login
